[HTML][HTML] Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study

…, I Eckerle, N Vuilleumier, B Meyer, A Flahault, L Kaiser… - The Lancet, 2020 - thelancet.com
Background Assessing the burden of COVID-19 on the basis of medically attended case
numbers is suboptimal given its reliance on testing strategy, changing case definitions, and …

Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations

L Kaiser, C Wat, T Mills, P Mahoney… - Archives of internal …, 2003 - jamanetwork.com
Background Influenza causes lower respiratory tract complications (LRTCs), particularly
bronchitis and pneumonia, in both otherwise healthy adults and those with underlying conditions…

[HTML][HTML] Long-term consequences of COVID-19: research needs

…, A Bandera, L Scudeller, M Paul, L Kaiser… - The Lancet Infectious …, 2020 - thelancet.com
Weeks and months after the onset of acute COVID-19, people continue to suffer. Paul Garner,
a professor of epidemiology at Liverpool School of Tropical Medicine, UK, wrote on the …

[HTML][HTML] Beyond malaria—causes of fever in outpatient Tanzanian children

…, C Lengeler, P Cherpillod, L Kaiser… - … England Journal of …, 2014 - Mass Medical Soc
Background As the incidence of malaria diminishes, a better understanding of nonmalarial
fever is important for effective management of illness in children. In this study, we explored …

[HTML][HTML] Infectious viral load in unvaccinated and vaccinated individuals infected with ancestral, Delta or Omicron SARS-CoV-2

…, C Genecand, A Iten, F Jacquérioz, L Kaiser… - Nature medicine, 2022 - nature.com
Infectious viral load (VL) expelled as droplets and aerosols by infected individuals partly
determines transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). …

Influenza virus neuraminidase inhibitors

LV Gubareva, L Kaiser, FG Hayden - The Lancet, 2000 - thelancet.com
Neuraminidase promotes influenza virus release from infected cells and facilitates virus
spread within the respiratory tract. Several potent and specific inhibitors of this enzyme have …

[HTML][HTML] Novel SARS-CoV-2 variants: the pandemics within the pandemic

…, I Kronig, RA Neher, I Eckerle, P Vetter, L Kaiser - Clinical Microbiology …, 2021 - Elsevier
Background Many new variants of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
have been termed variants of concern/interest (VOC/I) because of the greater risk …

[HTML][HTML] Phase 1 trials of rVSV Ebola vaccine in Africa and Europe

…, S Zaki, P Fast, V Moorthy, L Kaiser… - … England Journal of …, 2016 - Mass Medical Soc
Background The replication-competent recombinant vesicular stomatitis virus (rVSV)–based
vaccine expressing a Zaire ebolavirus (ZEBOV) glycoprotein was selected for rapid safety …

Picornavirus and enterovirus diversity with associated human diseases

C Tapparel, F Siegrist, TJ Petty, L Kaiser - Infection, Genetics and Evolution, 2013 - Elsevier
Members of the Picornaviridae family are non-enveloped, positive-stranded RNA viruses
with a 30nm icosahedral capsid. This virus family exhibits a considerable amount of genetic …

Serology-informed estimates of SARS-CoV-2 infection fatality risk in Geneva, Switzerland

J Perez-Saez, SA Lauer, L Kaiser, S Regard… - The Lancet Infectious …, 2021 - thelancet.com
The infection fatality risk (IFR) is the average number of deaths per infection by a pathogen
and is key to characterising the severity of infection across the population and for specific …